LIST OF FIGURES

Figure 1.1: Number of people with diabetes in the adult population by region and year.

Figure 1.2: Mechanism of formation of advanced glycation end products (AGEs).

Figure 1.3: Structural formulae of different AGEs.

Figure 1.4: Plasma proteome.

Figure 2.1: MALDI-MS analysis of in vitro glycated proteins (A) Insulin (B) Apomyoglobin (C) Papain (D) BSA (E) HSA (F) IgG.

Figure 2.2: Increase in mass of six proteins on 3rd, 6th, and 10th day of glycation reaction monitored by MALDI-MS.

Figure 2.3: Relationship between protein molecular mass and increase in protein mass (A) day 3 (B) day 6 (C) day 10.

Figure 2.4: Effect of albumin concentration on insulin glycation (A) 0 mg/ml albumin, (B) 5 mg/ml albumin, (C) 10 mg/ml albumin, (D) 50 mg/ml albumin. These spectra were acquired on a positive reflector mode by MALDI-MS.

Figure 2.5: MALDI-MS analysis of (A) unglycated albumin (B) glycated albumin.

Figure 2.6: Effect of albumin concentration on apomyoglobin glycation (A) 0 mg/ml albumin, (B) 5 mg/ml albumin, (C) 25 mg/ml albumin (D) 50 mg/ml albumin.

Figure 2.7: Relationship between ratio of absolute intensity value of glycated and unglycated peaks of apomyoglobin and HSA concentration.

Figure 2.8: Effect of carbonic anhydrase (CA) and papain on insulin glycation (A) 0 mg/ml CA, (B) 2 mg/ml CA, (C) 0 mg/ml papain, (D) 2 mg/ml papain.

Figure 3.1: Histopathology of kidney and liver tissue of Balb/C mice.

Figure 3.2: Scheme depicting glycated plasma protein identification from non diabetic and diabetic samples.

Figure 3.3: Representative (A) total ion count (TIC) chromatogram and (B) base peak intensity (BPI) chromatogram of clinical diabetic plasma using
nano-LC-ESI-MS

Figure 3.4: Total number of proteins and glycated proteins identified by LCMS in both mice and clinical plasma

Figure 3.5: Targeted database search for analysis of glycation modification in glycated proteins

Figure 3.6: A representative MS/MS annotation of glycation modification of carboxyethyllysine (CEL) showing increase in mass of 72.0154 Da

Figure 3.7: Heat map analysis of glycation modification sites on glycated proteins of (A) mice plasma (B) clinical plasma (C) in vitro glycated plasma

Figure 3.8: 2DE and western blot analysis of glycated proteins (A) mice plasma (B) clinical plasma (C) in vitro glycated plasma

Figure 3.9: Co-relation between albumin and HbA1c levels (A) mice plasma (B) clinical plasma

Figure 3.10: Mechanism of glycation regulation by albumin

Figure 4.1: Differential protein expression study by 2DE

Figure 4.2: Dot blot analysis of ten ND, CD and PCD samples using anti-apo A1 antibody